Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...

HURA READ THE FULL HURA RESEARCH REPORT We are initiating coverage of TuHURA Biosciences, Inc. (NASDAQ:HURA) with a valuation ...

MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer ...

Shifts Focus with Acquisition of LipoVation Ltd., Advancing Nanoparticle-Based Drug DevelopmentIsrael, Feb. 04, 2025 (GLOBE ...

In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve treatment outcomes for patients with high-risk early-stage triple-negative ...

Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company pioneering innovative cancer and viral infection treatments, today announced the ...

MAIA Biotechnology (MAIA) announced updated data from its THIO-101 pivotal Phase 2 clinical trial evaluating its lead clinical candidate, THIO, ...

Financial GeoVax Anticipates Significant 2025 Progress With Catalyst-Rich Milestones Across Key Programs 05.02.2025 / 15:06 CET/CEST The issuer is solely responsible for the content of this ...

BIO CEO & Investor conference Format: "IPO Class of 2024 Panel" and one-on-one meetings Date: February 10, 2025 Location: New York, NY Registered conference attendees may schedule one-on-one meetings ...

Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.

Scientists have progressed from merely provoking an anti-cancer immune response to designing it ...

CHICAGO - MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company with a market capitalization of $49.4 million, has announced updated data from its Phase 2 clinical ...